靶向SHP2信号在肺癌中的作用

2023-09-15 09:54

最大的挑战仍然是确定最佳耐受和有效的组合。几项正在进行的临床试验的结果将揭示SHP2抑制剂的功效。

SCI

14 September 2023

Targeting SHP2 Signaling in Lung Cancer

(J Thorac Oncol; IF:20.4)

Corresponcence to:

Bruna Pellini, M.D.

H. Lee Moffitt Cancer Center

Department of Thoracic Oncology

12902 Magnolia Drive, Tampa, FL 33612

E-mail: bruna.pellini@moffitt.org

Imbody D, Arce K, Solanki HS, Haura EB, Pellini B, Targeting SHP2 Signaling in Lung Cancer, Journal of Thoracic Oncology (2023), doi: https://doi.org/10.1016/j.jtho.2023.08.009

SHP2 is a non-receptor protein tyrosine phosphatase that plays an important role in various signaling cascades involved in cell proliferation, differentiation, and survival. While SHP2 can act as a negative regulator of the JAK2/STAT3 pathway, it can also act as a positive regulator of the MAPK and PI3K pathway. Although SHP2 inhibitors have shown potential as monotherapy, their optimal use is likely in combination with other agents to synergize with them or to overcome therapy acquired resistance. The challenge remains to identify the best tolerable and efficacious combination. The results of several ongoing clinical trials will shed light into the efficacy of SHP2 inhibitors.

SHP2是一种非受体蛋白酪氨酸磷酸酶，在涉及细胞增殖、分化和存活的各种信号级联反应中起重要作用。虽然SHP2可以作为JAK2/STAT3通路的负调控因子，但它也可以作为MAPK和PI3K通路的正调控因子。尽管SHP2抑制剂已显示出作为单一疗法的潜力，但其最佳用途可能是与其他药物联合使用，从而与它们协同作用或克服获得性耐药。最大的挑战仍然是确定最佳耐受和有效的组合。几项正在进行的临床试验的结果将揭示SHP2抑制剂的功效。